Table 2 Baseline demographics and clinical characteristics of the OnabotulinumtoxinA 155 U e 195 U treated groups
|  | OnabotulinumtoxinA 155 U (n = 132) | OnabotulinumtoxinA 195 U (n = 143) | t/χ2 | P value |
|---|---|---|---|---|
Mean age, years | 43.2 ± 13.5 (range 18–76 years) | 44.9 ± 12.7 (range 18–78 years) | 1.08 | 0.289 |
Female, % (n) | 81.8 (108) | 79.7 (114) | 0.08 | 0.773 |
Diagnosis of chronic migraine, years | 7.6 ± 4.3 (range 0.5–10) | 8.4 ± 4.7 (range 1–12 years) | 1.47 | 0.143 |
Years from the onset of chronic migraine | 10.2 ± 4.8 (range 1–40) | 9.3 ± 5.1 (range 1–40 years) | 1.50 | 0.133 |
Monthly headache days | 22.3 ± 4.1 | 22.2 ± 4.9 | 0.19 | 0.850 |
Monthly migraine days | 21.4 ± 4.3 | 21.6 ± 4.8 | 0.34 | 0.734 |
Monthly pain medication intake days | 20.8 ± 4.5 | 21 ± 5.1 | 0.31 | 0.757 |
Mean HIT-6 score | 68.9 ± 4.3 | 67.9 ± 4.2 | 1.64 | 0.102 |
Patients with severe HIT-6, % (n) | 93.9 (124) | 95.8 (137) | 0.18 | 0.668 |